Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis
Source : https://www.msard-journal.com/article/S2211-0348(22)00184-5/fulltext
Delayed-release dimethyl fumarate (DMF; Tecfidera, Biogen, Weston, MA) is an oral disease-modifying therapy (DMT) approved for the treatment of adult patients with relapsing multiple sclerosis (RMS) (Tecfidera, 2014). During the first year of DMF treatment, lymphocyte counts decrease by approximately 30% and then stabilize (Gold et al., 2012; Fox et al., 2012, 2016).
Conclusions: A pronounced reduction in ALCs early after initiation of DMF in MS patients is the best predictive risk factor for the subsequent development of significant lymphopenia.